Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho to Investigate Price Agreement Rate as of End of June
July 21, 2008
- R&D NEWS IN BRIEF
July 21, 2008
- Ranbaxy Categorically Denies Allegations
July 21, 2008
- Korosho Gives Up Development of 2 Unapproved Drugs
July 21, 2008
- Nippon Kayaku to Actively Invest in Macromolecular Anticancer Agents
July 21, 2008
- Korosho Calls For Commercialization of Cures of Alzheimer's Disease in 10 Years
July 21, 2008
- Ferring Accelerates Business Development in Japan Aiming at \30 Bil. Sales in 2017
July 21, 2008
- Daiichi Sankyo to Collaborate with Seattle Genetics to Develop ADC Drugs
July 21, 2008
- Daiichi Sankyo Enters \88 Bil. Market for NSAID Tapes with Loxonin
July 21, 2008
- Kyowa Hakko Starts Developing siRNA Drugs in Earnest
July 21, 2008
- MEDICAL DEVICE NEWS IN BRIEF
July 21, 2008
- REGULATORY NEWS IN BRIEF
July 21, 2008
- Korosho Takes into Account US Opposition to More Frequent Drug Price Revisions
July 21, 2008
- 70 Amlodipine Generics Listed from 34 Companies
July 14, 2008
- Initial Goals in Action Program for Generics Almost Met
July 14, 2008
- Pharmacists Explain Generics to Only 11% of Patients: Survey
July 14, 2008
- GENERICS NEWS IN BRIEF
July 14, 2008
- Armala May Outperform Sutent: ASCO 2008 Key Highlight Seminar
July 14, 2008
- Pfizer's Research Center Split Off to Create RaQualia
July 14, 2008
- 2008 Innovative DDS
July 14, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…